Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Coherus BioSciences, Inc. - Common Stock
(NQ:
CHRS
)
0.7561
-0.0190 (-2.45%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 23, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Coherus BioSciences, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Analyst Expectations for Coherus BioSciences's Future
October 23, 2023
Via
Benzinga
Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 14, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Why Coherus BioSciences Stock Popped Today
October 05, 2023
Coherus resubmitted a license application for a key product today. Here's what investors need to know.
Via
The Motley Fool
Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™
October 05, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch
October 04, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
4 Analysts Have This to Say About Coherus BioSciences
September 26, 2023
Via
Benzinga
Why Coherus BioSciences Stock Popped Today
August 03, 2023
The immuno-oncology leader delivered a strong second quarter.
Via
The Motley Fool
Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day
October 02, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
September 27, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
FDA Strikes Off Coherus BioSciences' New Injector Biosimilar Treatment For Cancer Patients
September 25, 2023
The FDA issued a Complete Response Letter regarding the Biologics License Application supplement for Udenyca Onbody, Coherus BioSciences Inc's (NASDAQ: CHRS) on-body injector (OBI) presentation of...
Via
Benzinga
Exposures
Product Safety
FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections
September 25, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Analyst Ratings for Coherus BioSciences
August 03, 2023
Via
Benzinga
Earnings Preview For Coherus BioSciences
August 01, 2023
Via
Benzinga
Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
September 25, 2023
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138.
Via
Benzinga
Coherus BioSciences Announces New Employment Inducement Grants
September 22, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus Completes Surface Oncology Acquisition
September 08, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Why Coherus BioSciences Stock Was Plunging This Week
September 08, 2023
The "index effect" is real, although typically not long-lasting.
Via
The Motley Fool
Airbnb, Blackstone Rise On News They'll Join S&P 500 Index
September 02, 2023
ABNB and BX will join Sept. 18 as part of a quarterly rebalancing.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Coherus BioSciences to Participate at Upcoming September Investor Conferences
September 01, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences
August 31, 2023
Urges Stockholders to Vote Promptly to Ensure Their Shares are Represented at the September 7th Special Meeting
From
Surface Oncology, Inc.
Via
GlobeNewswire
Coherus BioSciences Announces New Employment Inducement Grants
August 22, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Why Cummins Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
August 03, 2023
Gainers Bluejay Diagnostics, Inc. (NASDAQ: BJDX) shares jumped 75% to $9.60.
Via
Benzinga
Clorox, Boot Barn, Herbalife, Upwork And Other Big Stocks Moving Higher On Thursday
August 03, 2023
U.S. stocks traded lower, with the Dow Jones falling around 100 points on Thursday. Here are some big stocks recording gains in today’s session. Traeger, Inc. (NYSE: COOK) shares jumped 43.2% to $5.90...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
August 02, 2023
Via
Benzinga
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
August 02, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023
July 26, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023
July 24, 2023
Via
Benzinga
Coherus BioSciences Announces New Employment Inducement Grants
July 21, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors
July 20, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Mark Cuban's Pharmacy Company Lands Deal With Top 10 US Retailer: Here Are The Details
July 19, 2023
Since launching the Mark Cuban Cost Plus Drug Company in 2022, entrepreneur and NBA team owner Mark Cuban has been on a mission to lower the cost of medicines for consumers.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.